ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients With Prostate Cancer -

Name: ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients With Prostate Cancer -
Creator: Vivli
Published: 2024-10-10T20:52:34+08:00

DataCite Commons2025-06-01 更新2026-05-07 收录

前列腺癌激素治疗

药物剂量优化

数据链接：

https://search.vivli.org/doiLanding/studies/PR00010681/isLanding 数据链接链接失效反馈

官方服务：

资源简介：

To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.

提供机构：

Vivli

创建时间：

2024-10-10

Available IPD datapackage for study 'A Multicenter Randomized Placebo-Controlled Phase II Study of the Human Anti-TNF Antibody D2E7 Administered as Subcutenous Injections in Rheumatoid Arthritis Patients Treated with Methotrexate.'

类风湿关节炎治疗反应

抗TNF治疗

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot

DataCite Commons2025-01-06 更新40

An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week in Patients With Type 2 Diabetes Mellitus

糖尿病药物疗效

连续血糖监测

This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administ

DataCite Commons2025-10-01 更新20

Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study

糖尿病治疗优化

GLP-1受体激动剂疗效

This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglu

DataCite Commons2025-12-08 更新10

A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer

乳腺癌药物治疗

临床评估

The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed ad

DataCite Commons2024-12-02 更新20

A Randomised, Open-Label, Crossover, Phase I Study to Assess the Effect of Itraconazole, a CYP3A4 Inhibitor, on the Pharmacokinetics of ZD1839 at Doses of 250 and 500 mg in Healthy Male Subjects

药物相互作用

药代动力学

DataCite Commons2024-12-02 更新20